HK1210140A1 - 作為 複合物的抑制劑的稠合嘧啶 - Google Patents

作為 複合物的抑制劑的稠合嘧啶

Info

Publication number
HK1210140A1
HK1210140A1 HK15110723.6A HK15110723A HK1210140A1 HK 1210140 A1 HK1210140 A1 HK 1210140A1 HK 15110723 A HK15110723 A HK 15110723A HK 1210140 A1 HK1210140 A1 HK 1210140A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
complex
fused pyrimidines
pyrimidines
fused
Prior art date
Application number
HK15110723.6A
Other languages
English (en)
Inventor
周漢杰
．帕拉蒂
．武斯特羅
Original Assignee
Cleave Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1210140(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cleave Biosciences Inc filed Critical Cleave Biosciences Inc
Publication of HK1210140A1 publication Critical patent/HK1210140A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15110723.6A 2012-07-20 2015-10-29 作為 複合物的抑制劑的稠合嘧啶 HK1210140A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261674144P 2012-07-20 2012-07-20
US201261737666P 2012-12-14 2012-12-14
PCT/US2013/051358 WO2014015291A1 (en) 2012-07-20 2013-07-19 FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX

Publications (1)

Publication Number Publication Date
HK1210140A1 true HK1210140A1 (zh) 2016-04-15

Family

ID=48948500

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110723.6A HK1210140A1 (zh) 2012-07-20 2015-10-29 作為 複合物的抑制劑的稠合嘧啶

Country Status (19)

Country Link
US (3) US9475824B2 (zh)
EP (2) EP2875018B1 (zh)
JP (2) JP6109937B2 (zh)
KR (1) KR101862912B1 (zh)
CN (2) CN104768946B (zh)
AU (1) AU2013292309B2 (zh)
BR (1) BR112015001213A2 (zh)
CA (1) CA2879789C (zh)
CL (1) CL2015000132A1 (zh)
EA (1) EA030687B1 (zh)
ES (1) ES2667726T3 (zh)
HK (1) HK1210140A1 (zh)
HU (1) HUE037190T2 (zh)
IL (1) IL236812B (zh)
MX (1) MX2015000908A (zh)
NZ (1) NZ705040A (zh)
TW (1) TWI614246B (zh)
WO (1) WO2014015291A1 (zh)
ZA (1) ZA201500953B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010554B2 (en) 2012-07-20 2018-07-03 Cleave Biosciences, Inc. Fused pyrimidines as inhibitors of P97 complex

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
JPWO2015005491A1 (ja) 2013-07-12 2017-03-02 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
ES2708577T3 (es) 2013-09-04 2019-04-10 Univ Kyoto Composición medicinal que mejora la resistencia a la leptina
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3080101A1 (en) 2013-12-10 2016-10-19 Cleave Biosciences, Inc. Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex
WO2015109285A1 (en) * 2014-01-20 2015-07-23 Cleave Biosciences, Inc. FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
US20170159101A1 (en) * 2014-07-09 2017-06-08 Cleave Biosciences, Inc. Drug-resistant p97 atpase mutations
TW201617368A (zh) * 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016154110A1 (en) * 2015-03-20 2016-09-29 Cleave Biosciences, Inc. Companion diagnostic for p97 inhibitor therapy and methods of use thereof
WO2016200840A1 (en) * 2015-06-08 2016-12-15 Cleave Biosciences, Inc. Mono and bicyclic ring boronic acid, ester and salt compounds as inhibitors of p97 complex
US11312690B2 (en) * 2015-07-24 2022-04-26 University Of Lousville Research Foundation, Inc. Compounds, compositions, methods for treating diseases, and methods for preparing compounds
EP3356348B1 (en) * 2015-10-02 2021-05-05 Sentinel Oncology Limited 2-aminoquinazoline derivatives as p70s6 kinase inhibitors
WO2017070320A1 (en) 2015-10-21 2017-04-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Phenyl indole allosteric inhibitors of p97 atpase
IT201600070952A1 (it) * 2016-07-07 2018-01-07 Univ Degli Studi Di Ferrara NUOVI TIAZOLO[5,4-d]PIRIMIDIN DERIVATI QUALI AGONISTI INVERSI DEI RECETTORI A2A DELL’ADENOSINA
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
IT201600130706A1 (it) 2016-12-23 2018-06-23 Fondazione St Italiano Tecnologia 4 amino-2-pirido-biciclo pirimidine e lo uso come medicamenti
WO2019099402A1 (en) * 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
AU2018369787B2 (en) * 2017-11-16 2023-04-20 Principia Biopharma Inc. Immunoproteasome inhibitors
WO2019133904A1 (en) * 2017-12-30 2019-07-04 Unity Biotechnology, Inc. Inhibitors of hsp90, pi3-kinase, proteasome, hdac, and p97 pathways for selective removal of senescent cells in the treatment of age related conditions
TW201942116A (zh) * 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
US20230096028A1 (en) * 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CN110339828B (zh) * 2019-07-19 2020-08-11 浙江大学 以苯并噻唑基硫代羧酸为功能配基的层析介质及其制备方法
EP4055017A1 (en) 2019-11-08 2022-09-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
JP2022170472A (ja) * 2021-04-28 2022-11-10 国立大学法人京都大学 皮膚組織の異常を改善するための組成物
GB202111193D0 (en) 2021-08-03 2021-09-15 Phoremost Ltd Pharmaceutical compounds
CN114105887B (zh) * 2021-09-16 2023-12-01 沈阳药科大学 一种氨基嘧啶衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
US7741432B2 (en) 2005-05-27 2010-06-22 Proteolix, Inc. Substrate for Rpn11 enzymatic activity
US8273700B2 (en) * 2005-09-29 2012-09-25 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
EP2158207B1 (en) 2007-06-12 2011-05-25 F. Hoffmann-La Roche AG Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
US8637560B2 (en) * 2007-07-18 2014-01-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
CN102480961A (zh) 2009-06-24 2012-05-30 健泰科生物技术公司 与含氧杂环稠合的嘧啶化合物、组合物和使用方法
MX2012001449A (es) * 2009-08-10 2012-03-26 Hoffmann La Roche Inhibidores de cinasas c-jun-n-terminales (jnk).
AU2011249859B2 (en) * 2010-05-07 2014-07-03 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
JP2013166700A (ja) 2010-06-02 2013-08-29 Dainippon Sumitomo Pharma Co Ltd 新規４，５−縮環ピリミジン誘導体
KR101862912B1 (ko) 2012-07-20 2018-05-30 클리브 바이오사이언스 인코포레이티드 (클리브) p97 복합체의 저해제로서의 축합된 피리미딘

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010554B2 (en) 2012-07-20 2018-07-03 Cleave Biosciences, Inc. Fused pyrimidines as inhibitors of P97 complex

Also Published As

Publication number Publication date
HUE037190T2 (hu) 2018-08-28
CN104768946A (zh) 2015-07-08
JP2017125053A (ja) 2017-07-20
US20170258795A1 (en) 2017-09-14
CA2879789C (en) 2019-08-20
TW201414728A (zh) 2014-04-16
EP2875018A1 (en) 2015-05-27
US20150239907A1 (en) 2015-08-27
KR20150032588A (ko) 2015-03-26
CN104768946B (zh) 2017-05-03
CN107459508A (zh) 2017-12-12
MX2015000908A (es) 2015-09-21
JP6109937B2 (ja) 2017-04-05
ES2667726T3 (es) 2018-05-14
NZ705040A (en) 2017-07-28
US10010554B2 (en) 2018-07-03
KR101862912B1 (ko) 2018-05-30
TWI614246B (zh) 2018-02-11
CA2879789A1 (en) 2014-01-23
AU2013292309A1 (en) 2015-03-05
ZA201500953B (en) 2016-01-27
CL2015000132A1 (es) 2015-10-02
IL236812B (en) 2019-03-31
US9062026B2 (en) 2015-06-23
US20140024661A1 (en) 2014-01-23
EP2875018B1 (en) 2018-02-14
EA030687B1 (ru) 2018-09-28
US9475824B2 (en) 2016-10-25
EP3208270A1 (en) 2017-08-23
BR112015001213A2 (pt) 2018-05-22
WO2014015291A1 (en) 2014-01-23
EA201590255A1 (ru) 2015-07-30
AU2013292309B2 (en) 2017-05-25
JP2015526420A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
HK1210140A1 (zh) 作為 複合物的抑制劑的稠合嘧啶
HRP20181862T1 (hr) Inhibitori dna-pk
HK1201266A1 (zh) 作為 抑制劑的稠合的四元或五元環吡啶並酞嗪酮類化合物
HRP20171883T1 (hr) Kondenzirani tetra ili penta-ciklički dihidrodiazepinokarbazoloni kao parp inhibitori
ZA201605107B (en) Fused pyrimidines as inhibitors of p97 complex
GB2506496B (en) Superhard constructions & methods of making same
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
HK1211024A1 (zh) 的抑制劑
EP2847186A4 (en) SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑
EP2892529A4 (en) USES OF (-) - PERHEXILINE
GB201321220D0 (en) Superhard constructions & methods of making same
EP2922823A4 (en) PDE10 PYRIMIDININHIBITOREN
GB2506357B (en) Machining of an article
GB201217666D0 (en) Construction of surfaces